Improving prognosis of glioblastoma in the 21st century: who has benefited most?

摘要: BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. Temozolomide was rapidly incorporated into first-line treatment following publication of pivotal European Organization for Research and Treatment Cancer–National Cancer Institute Canada phase 3 trial 2005. However, trial, enrollment limited to younger patients with good performance status. Therefore, this study performed a population-based survival analysis newly diagnosed GBM covering period before after introduction temozolomide. METHODS: Survival statistics clinical demographic variables were extracted from Survival, Epidemiology End Results Database 2001 2007. Mean regional income each patient also collected. Survival analyzed using Kaplan-Meier method proportional hazard models. RESULTS: A total 13,003 adult identified. Prognostic included age <70 years, use radiation, gross resection, residence high-income district (P < .001). Between 2007, median time increased 7 9 months entire population. The 1-year 29% 39%. Prognosis aged 70 or more years did not improve over time. Over period, absolute disparity between low- districts 6.6% 10.1%. CONCLUSIONS: There has been stepwise improvement overall This confined prominent among living districts. 2012. © 2011 American Society.